Morgan Stanley Bellus Health Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$7.14 - $8.53 $697,335 - $833,090	97,666 Added 37.04%	361,311 $2.6 Million
Q4 2022 Feb 14, 2023	SELL	$8.22 - $10.76 $1.26 Million - $1.65 Million	-153,376 Reduced 36.78%	263,645 $2.17 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $2.63 Million - $3.53 Million	294,293 Added 239.79%	417,021 $4.41 Million
Q2 2022 Oct 27, 2022	SELL	$6.46 - $10.02 $1.12 Million - $1.73 Million	-172,822 Reduced 58.47%	122,728 $1.13 Million
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $1.12 Million - $1.73 Million	-172,822 Reduced 58.47%	122,728 $1.13 Million
Q1 2022 Oct 27, 2022	BUY	$5.56 - $7.99 $960,890 - $1.38 Million	172,822 Added 140.82%	295,550 $2.03 Million
Q1 2022 May 13, 2022	BUY	$5.56 - $7.99 $1.31 Million - $1.88 Million	235,902 Added 395.49%	295,550 $2.03 Million
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $93,643 - $147,764	-17,803 Reduced 22.99%	59,648 $481,000
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $209,117 - $514,274	77,451 New	77,451 $476,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.